A Phase I/II Trial of Everolimus and Lonafarnib in Progeria

Recruiting by Invitation Phase 1,Phase 2 NCT02579044

Study Description

A Study to Test the Safety and Effectiveness of Everolimus Combined with Lonafarnib in Children with Progeria

Study Details

Registry ID:: NCT02579044
Conditions:: Progeria
Phase:: Phase 1,Phase 2
Target Enrollment:: 80 participants
Start Date:: December 1, 2015
Age Range:: 1.5–25 years
Healthy Volunteers:: No

Study Locations (1 site)

Boston Children's Hospital
Boston, MassachusettsUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →